Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer
Crossref DOI link: https://doi.org/10.1007/s00520-017-3950-y
Published Online: 2017-10-31
Published Print: 2018-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Bubalo, Joseph S.
Herrington, Jon D.
Takemoto, Marc
Willman, Patricia
Edwards, Michael S.
Williams, Casey
Fisher, Alan
Palumbo, Alison
Chen, Eric
Blanke, Charles
Lopez, Charles D.
Funding for this research was provided by:
Merck (US)
License valid from 2017-10-31